Implantable Cardioverter-defibrillator Therapy for Hypertrophic Cardiomyopathy: Usefulness in Primary and Secondary Prevention
- 1 June 2015
- journal article
- research article
- Published by Elsevier in Revista Española de Cardiología (English Edition)
- Vol. 68 (6) , 492-496
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markersEP Europace, 2010
- Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathyHeart, 2007
- ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm SocietyEP Europace, 2006
- Historical trends in reported survival rates in patients with hypertrophic cardiomyopathyHeart, 2005
- American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic CardiomyopathyJACC, 2003
- Valor del ecocardiograma-Doppler en el pronóstico y en el seguimiento de la miocardiopatía hipertróficaRevista Espanola de Cardiologia, 2001
- Sudden death in hypertrophic cardiomyopathy: identification of high risk patientsJACC, 2000
- Epidemiology of Hypertrophic Cardiomyopathy–Related DeathCirculation, 2000
- Efficacy of Implantable Cardioverter–Defibrillators for the Prevention of Sudden Death in Patients with Hypertrophic CardiomyopathyNew England Journal of Medicine, 2000
- Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathyJACC, 1999